Ocugen (OCGN) to Release Earnings on Friday

Ocugen (NASDAQ:OCGN - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Friday, August 1st. Analysts expect Ocugen to post earnings of ($0.06) per share and revenue of $0.35 million for the quarter.

Ocugen (NASDAQ:OCGN - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Ocugen had a negative return on equity of 223.00% and a negative net margin of 1,271.12%. The business had revenue of $1.48 million for the quarter. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ocugen Stock Down 5.5%

OCGN stock traded down $0.06 on Monday, hitting $1.03. 3,321,745 shares of the company's stock were exchanged, compared to its average volume of 4,159,794. Ocugen has a 12-month low of $0.52 and a 12-month high of $1.66. The firm has a 50 day moving average price of $1.01 and a two-hundred day moving average price of $0.80. The company has a debt-to-equity ratio of 1.74, a quick ratio of 2.60 and a current ratio of 2.60. The stock has a market cap of $300.79 million, a P/E ratio of -5.42 and a beta of 4.18.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Ocugen in a research note on Tuesday, June 24th. Chardan Capital reissued a "buy" rating and set a $7.00 target price on shares of Ocugen in a report on Tuesday, June 24th.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.